ArticleOncotarget2017
Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- The Value of a Seven-Autoantibody Panel Combined with the Mayo Model in the Differential Diagnosis of Pulmonary Nodules.Disease markers · 2021Trial
- Stage-specific lipidomic signatures as biomarkers in progression of cervical cancer.The Indian journal of medical research · 2026Article
- Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics.Diagnostics (Basel, Switzerland) · 2025Review
- Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis-a narrative review.Translational lung cancer research · 2025Review
- Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.ACS pharmacology & translational science · 2025Review
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice.Life (Basel, Switzerland) · 2025Article
- Metabolomics Analysis and Diagnosis of Lung Cancer: Insights from Diverse Sample Types.International journal of medical sciences · 2024Review
- Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients.Journal of lipids · 2024Article
- Biomarkers in Cancer Detection, Diagnosis, and Prognosis.Sensors (Basel, Switzerland) · 2023Review
- Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study.Cancers · 2023Article
- Metabolic biomarkers in lung cancer screening and early diagnosis (Review).Oncology letters · 2023Review
- Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.Analytical and bioanalytical chemistry · 2023Article
- A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer.Vaccines · 2023Review
- Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis.Pharmaceutics · 2023Review
- Lipidomic profiles as a tool to search for new biomarkers.International journal of occupational medicine and environmental health · 2022Review
- Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls.Scientific reports · 2021Article
- Metabolomic Profiling in Lung Cancer: A Systematic Review.Metabolites · 2021Review
- Article
- Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.Frontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeLipids play roles in membrane structure, energy storage, and signal transduction as well as in human cancers. Here we adopt lipidomics to identify plasma lipid markers for early screening and detection of lung cancer. EXPERIMENTAL
designUsing mass spectrometry, we profiled 390 individual lipids using training and validation strategy in a total of 346 plasma samples from 199 early NSCLC patients, including 113 adenocacinoma and 86 squamous cell cancers (SqCC), and from 147 healthy controls.
resultsIn the training stage, we found distinct lipid groups that were significantly distributed between NSCLC cases and healthy controls. We further defined a panel of four lipid markers (LPE(18:1), ePE(40:4), C(18:2)CE and SM(22:0)) for prediction of early cancer with a accuracy of 82.3% AUC (Area under ROC curve), sensitivity of 81.9% and specificity of 70.7% at the training stage and yielded the predictive power with accuracy (AUC,80.8%), sensitivity 78.7%, specificity 69.4% and in the validation stage.
conclusionsUsing lipidomics we identified several lipid markers capable of discerning early stage lung carcinoma from healthy individuals, which might be further developed as a quick, safe blood test for early diagnosis of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.